• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

狼疮肾炎的治疗:新疗法和更新的指南。

Management of Lupus Nephritis: New Treatments and Updated Guidelines.

机构信息

Nephrology and Hypertension, Oregon Health & Science University School of Medicine, Portland, Oregon.

Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida.

出版信息

Kidney360. 2023 Oct 1;4(10):1503-1511. doi: 10.34067/KID.0000000000000230.

DOI:10.34067/KID.0000000000000230
PMID:37528520
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10617804/
Abstract

Management of lupus nephritis has evolved considerably over the past years. Here, we provide a comprehensive review of clinical trials that form the basis for the Kidney Disease: Improving Global Outcomes and EULAR/ERA-EDTA updated guidelines and present day trials that will change the landscape of lupus nephritis therapy in years to come. In addition, we highlight the issues related to cost of therapy, resistant disease, and downstream adverse effects of specific therapies.

摘要

狼疮肾炎的治疗在过去几年中已有了显著的发展。在这里,我们对构成改善全球肾脏病预后组织(KDIGO)和欧洲抗风湿病联盟/欧洲肾脏学会- 血管紧张素转化酶抑制剂分会(EULAR/ERA-EDTA)更新指南基础的临床试验进行了全面回顾,并介绍了目前的临床试验,这些试验将在未来几年改变狼疮肾炎治疗的格局。此外,我们还强调了与治疗成本、耐药疾病以及特定治疗方法的下游不良影响相关的问题。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ae2/10617804/eabdcac38563/kidney360-4-01503-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ae2/10617804/eabdcac38563/kidney360-4-01503-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ae2/10617804/eabdcac38563/kidney360-4-01503-g001.jpg

相似文献

1
Management of Lupus Nephritis: New Treatments and Updated Guidelines.狼疮肾炎的治疗:新疗法和更新的指南。
Kidney360. 2023 Oct 1;4(10):1503-1511. doi: 10.34067/KID.0000000000000230.
2
Immunosuppressive treatment for proliferative lupus nephritis.增殖性狼疮性肾炎的免疫抑制治疗
Cochrane Database Syst Rev. 2018 Jun 29;6(6):CD002922. doi: 10.1002/14651858.CD002922.pub4.
3
Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis.免疫抑制药物和糖皮质激素治疗狼疮性肾炎时发生严重感染的风险:一项系统评价和网状Meta分析
BMC Med. 2016 Sep 13;14(1):137. doi: 10.1186/s12916-016-0673-8.
4
Treatment for lupus nephritis.狼疮性肾炎的治疗。
Cochrane Database Syst Rev. 2012 Dec 12;12:CD002922. doi: 10.1002/14651858.CD002922.pub3.
5
Management of newly diagnosed lupus nephritis in China: An implementation study based on the 2023 EULAR recommendations.中国新诊断狼疮性肾炎的管理:一项基于2023年欧洲抗风湿病联盟(EULAR)建议的实施研究
Clin Rheumatol. 2025 Jun 7. doi: 10.1007/s10067-025-07520-x.
6
New guidelines and therapeutic updates for the management of lupus nephritis.狼疮肾炎治疗的新指南和治疗进展。
Curr Opin Nephrol Hypertens. 2024 May 1;33(3):344-353. doi: 10.1097/MNH.0000000000000969. Epub 2024 Feb 9.
7
Efficacy and safety of novel biologics in the treatment of lupus nephritis based on registered clinical trials: a systematic review and network meta-analysis.基于注册临床试验的新型生物制剂治疗狼疮性肾炎的疗效和安全性:一项系统评价和网状Meta分析
Clin Exp Med. 2023 Nov;23(7):3011-3018. doi: 10.1007/s10238-023-01132-y. Epub 2023 Jul 18.
8
Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis.霉酚酸酯用于狼疮性肾炎诱导治疗的系统评价和荟萃分析。
Clin J Am Soc Nephrol. 2007 Sep;2(5):968-75. doi: 10.2215/CJN.01200307. Epub 2007 Aug 8.
9
Treatment for lupus nephritis.狼疮性肾炎的治疗。
Cochrane Database Syst Rev. 2004(1):CD002922. doi: 10.1002/14651858.CD002922.pub2.
10
Mizoribine or Cyclophosphamide for Lupus Nephritis: A Randomized Clinical Trial.米唑立宾或环磷酰胺治疗狼疮性肾炎:一项随机临床试验。
JAMA Netw Open. 2025 Mar 3;8(3):e250648. doi: 10.1001/jamanetworkopen.2025.0648.

引用本文的文献

1
A Rare Case of Systemic Lupus Erythematosus in an Elderly Male With an Incidental Lung Mass: A Case Report.一名老年男性系统性红斑狼疮合并偶然发现的肺部肿块的罕见病例:病例报告
J Community Hosp Intern Med Perspect. 2025 May 5;15(3):73-75. doi: 10.55729/2000-9666.1471. eCollection 2025.
2
Ameliorative Effect of Combined Placenta-Derived Mesenchymal Stem Cells plus Platelet-rich Plasma on Polycystic Ovarian Model in Rats: A Biochemical and Histological Study.联合胎盘来源间充质干细胞加富血小板血浆对大鼠多囊卵巢模型的改善作用:一项生化与组织学研究
Reprod Sci. 2025 Mar;32(3):907-918. doi: 10.1007/s43032-025-01791-0. Epub 2025 Jan 24.
3

本文引用的文献

1
Discovery of seven novel putative antigens in membranous nephropathy and membranous lupus nephritis identified by mass spectrometry.通过质谱分析发现膜性肾病和狼疮性肾炎中七个新的潜在抗原。
Kidney Int. 2023 Mar;103(3):593-606. doi: 10.1016/j.kint.2023.01.001. Epub 2023 Jan 10.
2
Current Insights on Biomarkers in Lupus Nephritis: A Systematic Review of the Literature.狼疮性肾炎生物标志物的最新见解:文献系统评价
J Clin Med. 2022 Sep 28;11(19):5759. doi: 10.3390/jcm11195759.
3
Analysis of the Expression of Exostosins and Clinicopathological Features in Membranous Lupus Nephritis in a Chinese Cohort.
The Role of Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors in Treating Lupus Nephritis: A Systematic Review.
钠-葡萄糖协同转运蛋白2(SGLT-2)抑制剂在治疗狼疮性肾炎中的作用:一项系统评价
Cureus. 2024 Dec 21;16(12):e76130. doi: 10.7759/cureus.76130. eCollection 2024 Dec.
4
Effectiveness and safety of B cell-targeting biologics in the treatment of lupus nephritis: a systematic review and network meta‑analysis.B 细胞靶向生物制剂治疗狼疮肾炎的疗效和安全性:系统评价和网络荟萃分析。
Ren Fail. 2024 Dec;46(2):2416605. doi: 10.1080/0886022X.2024.2416605. Epub 2024 Oct 23.
5
Therapeutic JAK1 Inhibition Reverses Lupus Nephritis in a Mouse Model and Demonstrates Transcriptional Changes Consistent With Human Disease.治疗性JAK1抑制可逆转小鼠模型中的狼疮性肾炎,并显示出与人类疾病一致的转录变化。
ACR Open Rheumatol. 2024 Dec;6(12):900-911. doi: 10.1002/acr2.11745. Epub 2024 Oct 4.
6
Anti-Smith Antibodies as a Predictive Factor for Developing Lupus Nephritis in Systemic Lupus Erythematosus Patients: A Systematic Review.抗史密斯抗体作为系统性红斑狼疮患者发生狼疮性肾炎的预测因素:一项系统评价
Cureus. 2024 Aug 6;16(8):e66270. doi: 10.7759/cureus.66270. eCollection 2024 Aug.
7
Lupus Nephritis from Pathogenesis to New Therapies: An Update.狼疮性肾炎:从发病机制到新疗法的研究进展。
Int J Mol Sci. 2024 Aug 18;25(16):8981. doi: 10.3390/ijms25168981.
8
Proposal of a novel cardiovascular risk prediction score in lupus nephritis.狼疮性肾炎中一种新型心血管风险预测评分的提议。
Front Immunol. 2024 Jul 24;15:1405463. doi: 10.3389/fimmu.2024.1405463. eCollection 2024.
9
Efficacy and safety of telitacicept in patients with lupus nephritis.泰它西普治疗狼疮性肾炎患者的疗效和安全性。
Exp Ther Med. 2024 Jul 23;28(4):371. doi: 10.3892/etm.2024.12660. eCollection 2024 Oct.
中国队列中膜性狼疮性肾炎外生骨疣蛋白表达及临床病理特征分析
Kidney Int Rep. 2022 Aug 3;7(10):2295-2298. doi: 10.1016/j.ekir.2022.07.164. eCollection 2022 Oct.
4
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus.抗 CD19 CAR T 细胞疗法治疗难治性系统性红斑狼疮。
Nat Med. 2022 Oct;28(10):2124-2132. doi: 10.1038/s41591-022-02017-5. Epub 2022 Sep 15.
5
Transforming Growth Factor Beta Receptor 3 (TGFBR3)-Associated Membranous Nephropathy.转化生长因子β受体 3(TGFBR3)相关膜性肾病。
Kidney360. 2021 Jun 11;2(8):1275-1286. doi: 10.34067/KID.0001492021. eCollection 2021 Aug 26.
6
Type I interferon-related kidney disorders.I 型干扰素相关肾脏疾病。
Kidney Int. 2022 Jun;101(6):1142-1159. doi: 10.1016/j.kint.2022.02.031. Epub 2022 Mar 24.
7
Expert Perspective: An Approach to Refractory Lupus Nephritis.专家视角:难治性狼疮肾炎的治疗方法。
Arthritis Rheumatol. 2022 Jun;74(6):915-926. doi: 10.1002/art.42092. Epub 2022 Apr 25.
8
Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis.I 型干扰素抑制剂阿尼鲁单抗治疗活动性狼疮肾炎的 II 期随机试验。
Ann Rheum Dis. 2022 Apr;81(4):496-506. doi: 10.1136/annrheumdis-2021-221478. Epub 2022 Feb 10.
9
The Cost-Effectiveness of Belimumab and Voclosporin for Patients with Lupus Nephritis in the United States.贝鲁单抗和 voclosporin 治疗美国狼疮肾炎患者的成本效果分析。
Clin J Am Soc Nephrol. 2022 Mar;17(3):385-394. doi: 10.2215/CJN.13030921. Epub 2022 Feb 3.
10
Urine Proteomics and Renal Single-Cell Transcriptomics Implicate Interleukin-16 in Lupus Nephritis.尿液蛋白质组学和肾脏单细胞转录组学提示白细胞介素-16 在狼疮肾炎中的作用。
Arthritis Rheumatol. 2022 May;74(5):829-839. doi: 10.1002/art.42023. Epub 2022 Apr 16.